#### Detection of Mutations Associated with Variants of Concern Via High Throughput 1

- Sequencing of SARS-CoV-2 Isolated from NYC Wastewater 2
- 3
- Davida S. Smyth<sup>a,\*</sup>, Monica Trujillo<sup>b,\*</sup>, Kristen Cheung<sup>c,¶</sup>, Anna Gao<sup>c,¶</sup>, Irene Hoxie<sup>c,d,¶</sup>, Sherin Kannoly<sup>c,¶</sup>, Nanami Kubota<sup>c,¶</sup>, Michelle Markman<sup>c,¶</sup>, Kaung Myat San<sup>c,¶</sup>, Geena 4
- 5
- Sompanya<sup>a,¶</sup>, and John J. Dennehy<sup>c,d</sup>\* 6
- 7
- 8 <sup>a</sup>Department of Natural Sciences and Mathematics, Eugene Lang College of Liberal
- Arts at The New School, New York 9
- <sup>b</sup>Department of Biology, Queensborough Community College, The City University of 10 New York, New York 11
- <sup>c</sup>Biology Department, Queens College, The City University of New York, New York 12
- <sup>d</sup>Biology Doctoral Program, The Graduate Center, The City University of New York, New 13
- York 14
- 15
- Running title: Variants of Concern Detected in NYC Wastewater (47 characters) 16
- 17 \*Joint first authors
- <sup>¶</sup>Authors in alphabetical order 18
- <sup>#</sup>Address correspondence to: john.dennehy@gc.cuny.edu 19
- 20

# 21 ABSTRACT (186 words)

Monitoring SARS-CoV-2 genetic diversity is strongly indicated because diversifying 22 23 selection may lead to the emergence of novel variants resistant to naturally acquired or 24 vaccine-induced immunity. To date, most data on SARS-CoV-2 genetic diversity has 25 come from the sequencing of clinical samples, but such studies may suffer limitations 26 due to costs and throughput. Wastewater-based epidemiology may provide an alternative and complementary approach for monitoring communities for novel variants. 27 Given that SARS-CoV-2 can infect the cells of the human gut and is found in high 28 concentrations in feces, wastewater may be a valuable source of SARS-CoV-2 RNA, 29

- 30 which can be deep sequenced to provide information on the circulating variants in a
- community. Here we describe a safe, affordable protocol for the sequencing of SARS-
- 32 CoV-2 RNA using high-throughput Illumina sequencing technology. Our targeted
- 33 sequencing approach revealed the presence of mutations associated with several
- Variants of Concern at appreciable frequencies. Our work demonstrates that
- 35 wastewater-based SARS-CoV-2 sequencing can inform surveillance efforts monitoring
- the community spread of SARS-CoV-2 Variants of Concern and detect the appearance
- of novel emerging variants more cheaply, safely, and efficiently than the sequencing of
- 38 individual clinical samples.

### 39 **IMPORTANCE (140 words)**

- 40 The SARS-CoV-2 pandemic has caused millions of deaths around the world as
- 41 countries struggle to contain infections. The pandemic will not end until herd immunity is
- reached, that is, when most of the population has either recovered from SARS-CoV-2
- 43 infection or is vaccinated against SARS-CoV-2. However, the emergence of new SARS-
- 44 CoV-2 variants of concern threatens to erase gains. Emerging new variants may re-
- 45 infect persons who have recovered from COVID-19 or may evade vaccine-induced
- immunity. However, scaling up SARS-CoV-2 genetic sequencing to monitor Variants of
- 47 Concern in communities around the world is challenging. Wastewater-based
- 48 sequencing of SARS-CoV-2 RNA can be used to monitor the presence of emerging
- variants in large communities to enact control measures to minimize the spread of these
- variants. We describe here the identification of alleles associated with several variants
- of concern in wastewater obtained from NYC watersheds.
- 52 **KEYWORDS:** coronavirus, environmental microbiology, Illumina sequencing,
- 53 metagenomics, NGS, sewage, virus surveillance, Variants of Concern, wastewater-
- 54 based epidemiology

# 55 INTRODUCTION

- 56 The emergence of novel SARS-CoV-2 Variants of Concern, including B.1.1.7 from the
- 57 United Kingdom and B.1.351 from South Africa, has provoked intense speculation about
- the future of the pandemic (1-3). Early studies suggest that these new variants may be
- 59 more transmissible (4-6). Even more concerning are reports of decreased antibody-
- 60 mediated neutralization of these variants (7-9). Regardless of the biological attributes of

61 these novel variants, it is clear that behavioral interventions, public health measures,

- vaccinations, and reduced numbers of susceptible individuals will impose strong
- 63 diversifying selection on SARS-CoV-2 to enhance transmission and/or evade host
- 64 immunity (10). We should anticipate that the continued evolution of SARS-CoV-2 may
- result in variants that evade natural or vaccine-mediated immunity. As such, intensive
- 66 monitoring of SARS-CoV-2 genetic diversity and evolution is vital to rapidly identify
- 67 Variants of Concern as they emerge.

68 Currently, most SARS-CoV-2 genetic surveillance is conducted via the genome

- 69 sequencing of viral RNA obtained from clinical specimens. While occurring at a much
- greater rate and volume than previous epidemics, the sequencing of clinical specimens
- is limited by cost, coverage, quality, and throughput concerns. In developed countries,
- these issues are not readily apparent, but sequencing efforts in underdeveloped
- countries has been more restricted (11). Another disadvantage of focusing on clinical
- strains stems from the large number of asymptomatic or mildly symptomatic infections
- 75 (12). SARS-CoV-2 sequencing efforts will suffer biases if genomic information is more
- <sup>76</sup> frequently obtained from seriously ill patients, rather than from asymptomatic patients,
- and those with mild symptoms who choose to follow the CDC's advice and convalesce
- at home. Wastewater-based epidemiology may provide an alternative and
- complementary approach to provide more representative SARS-CoV-2 genetic data at
   lower costs and higher throughput.
- Given that SARS-CoV-2 has been detected in fecal samples (13, 14), and subsequently
- in wastewater, wastewater is being monitored in communities around the world to
- determine SARS-CoV-2 prevalence in communities (15-17). Furthermore, isolation of
- 84 SARS-CoV-2 RNA from wastewater coupled with high-throughput deep sequencing
- provides an almost unlimited source of unbiased viral sequences, which can be used to
- 86 monitor frequencies of Variants of Concern in populations (18-20). We have focused on
- 87 the use of targeted sequencing of the spike genomic region known to encode Variants
- 88 of Concern. Our approach, while limited to a specific region of the genome, is
- 89 affordable, rapid and generates sufficient coverage to quantify known variants and to
- 90 identify possible emerging ones.
- 91 Our team, in conjunction with the New York City Department of Environmental
- 92 Protection, has been monitoring the genetic signal of SARS-CoV-2 in the wastewater of
- all 14 wastewater treatment plants in NYC, an area that encompasses a population of
- 8,419,000 persons, since June 2020. We developed and optimized a protocol for safe,
- <sup>95</sup> cost-effective, and repeatable quantitation of SARS-CoV-2 copy number by RT-qPCR
- 96 (21). Our protocol performed strongly in a large-scale, nationwide comparative study of
- 97 the reproducibility and sensitivity of 36 methods of quantifying SARS-CoV-2 in
- 98 wastewater (22). Our protocol is identified as 4S.1(H) in Table 3. We further extended
- 99 the utility of our protocol by deep sequencing SARS-CoV-2 RNA isolated from
- 100 wastewater samples. Here we report presence of alleles associated with different
- 101 Variants of Concern at appreciable frequencies. Our findings provide support for recent

- 102 observations of increasing frequencies of New York Variant of Interest B.1.526 in
- 103 clinical samples (23, 24), as well as the presence of Variants of Concern from the
- 104 United Kingdom, California, South Africa and Brazil (25). Furthermore, our results
- demonstrate the utility of wastewater-based epidemiology for the timely identification of
- novel variants of concern arising in communities.

#### 107 **RESULTS AND DISCUSSION**

#### 108 Targeted sequencing is a viable approach for identifying SARS-C0V-2 mutations.

- 109 We generated cDNA from NYC wastewater samples that exhibited RT-qPCR Cts values
- ranging from 28 to 24 Cts corresponding to 26,443 and 1,423,339 N1 copies/L,
- respectively. Using this cDNA as a template, we PCR amplified a region of the receptor
- binding domain (RBD) of the SARS-CoV-2 Spike gene, spanning amino acid residues
- 113 P410 to L513, which encompasses mutations that are found in several known Variants
- of Concern. A total of 420 single nucleotide variants were identified in the 45 samples
- sequenced (Supplementary Table 1). Coverage ranged from 1,037x 118,737x with a
- mean of 23,586x (Supplementary Table 1). Across all samples, we identified 75 unique
- 117 mutations resulting in amino acid substitutions, 20 unique synonymous mutations, and
- 118 18 deletions resulting in a frameshift, in the 332 bp region targeted (Supplementary 119 Table 1).

# 120 Mutations associated with Variants of Concern are present in NYC wastewater.

- 121 The five mutations found at highest frequencies, both in terms of frequency of reads
- within samples and found in the most samples, were L452R, E484K, N501Y, S494P,
- and S477N. All five mutations are associated with known Variants of Concern (Fig. 1;
- 124 Supplementary Table 2). On Jan 31<sup>st</sup>, we sequenced samples from two wastewater
- treatment plants in NYC and identified reads containing mutations L452R, S477N,
- 126 E484K, S494P and N501Y in both. On February 28<sup>th</sup> and March 14<sup>th</sup> samples from all
- 127 14 wastewater treatment plants in NYC were sequenced, revealing the presence of a
- high proportion of reads containing mutations L452R, S477N, E484K, S494P and
- 129 N501Y (Fig. 1). Mutation L452R is unique to Pango lineage Variants of Concern
- B.1.427 and B.1.429, which were first observed in California (25, 26). Mutation S477N is
- only found in New York Variant of Interest B.1.526 (23-25, 27). Mutation E484K has
- been reported in Variants of Concern B.1.1.7 from the United Kingdom, P.1 and P.2
- from Brazil, and B.1.351 from South Africa, and B.1.525 and B.1.526 from New York
- (25). Mutation S494P is only found in Variant of Concern B.1.1.7 from the United
- 135 Kingdom (25). Mutation N501Y is found in Variants of Concern B.1.1.7 from the United
- Kingdom, P.1 from Brazil, and B.1.351 from South Africa (25).
- 137 The finding that unique mutations associated with different Variants of Concern in our
- pooled sequencing assay suggests the circulation of these variants in NYC. A caveat
- 139 with our approach, however, is that we cannot conclusively identify the presence of a
- 140 Variant of Concern since our sequencing assay targets only a region of the receptor
- binding domain, and some significant mutations are outside the sequenced region.
- 142 Furthermore, additional mutations occurring in the primer binding region may allow

- some mutations to go undetected because their DNA could not be amplified. We are
- expanding our targeted sequencing approach to include additional regions of interest to
- 145 minimize the chance of missing important variants. Additionally, we intend to generate
- 146 cDNA with random hexamers, and to incorporate a level of degeneracy in the
- sequencing primers to increase the breadth of our targeted sequencing.
- Our most recent data from March 14<sup>th</sup> suggests a slight decrease in the prevalence of
- the E484K variant, but we cannot draw firm conclusions due to the nature of our
- sequencing assay, which relies on the collective sequencing of a large pool of
- individuals. Nevertheless, our frequency data agrees with that recently observed in
- human clinical samples from NYC (23, 24, 27). We intend to supplement our targeted
- 153 sequencing approach with whole genome amplicon sequencing in the future.
- 154 We believe that our approach offers a viable alternative to whole genome sequencing
- 155 for the detection of known variants and can be rapidly deployed to detect additional
- emerging variants of concern. Importantly as a cost saving measure, labs can generate
- 157 the libraries themselves and outsource the sequencing component to companies/core
- 158 facilities if they lack access to a sequencer, generally with a short turnaround time.

# 159 MATERIALS AND METHODS

- 160 Wastewater Sample Processing and RNA Extraction. Wastewater was collected
- 161 from 14 NYC wastewater treatment plants and RNA isolated according to our previously
- published protocol (dx.doi.org/10.17504/protocols.io.brr6m59e) (21). Control SARS-
- 163 CoV-2 synthetic RNA was purchased from Twist Bioscience (#102019).
- Briefly, 250 mL from 24-hr composite raw sewage samples were obtained from NYC
- wastewater treatment plants (WWTPs) and centrifuged at 5,000 x g for 10 min at 4°C to
- pellet solids. 40 mL of supernatant was passed through a 0.22 µM filter. Filtrate was
- 167 stored at 4°C for 24 hrs after adding 0.9 g sodium chloride and 4.0 g PEG 8000 (Fisher)
- then centrifuged at 12,000 x g for 120 minutes at 4 °C to pellet precipitate. The pellet
- 169 was resuspended in 1.5 mL TRIzol (Fisher), and RNA was purified according to the
- 170 manufacturer's instructions.
- 171 **Targeted PCR.** Our target for sequencing was a 332 bp region of the Receptor Binding
- Domain (RBD) of the spike protein spanning amino acid residues P420 to L513.
- 173 Mutations in this region are of critical importance as they might help the variants evade
- current antibody treatments and vaccines. RNA isolated from wastewater was used to
- 175 generate cDNA using ProtoScript® II Reverse Transcriptase (New England Biolabs).
- 176 The RNA was incubated with an RBD specific primer (ccagatgattttacaggctgcg) and
- dNTPs (0.5 mM final concentration) at 65°C for 5 minutes and placed on ice. The RT
- buffer, DTT (0.01 M final concentration), and the RT were added to the same tube and
- incubated at 42°C for 2 hours followed by 20 minutes at 65°C to inactivate the enzyme.
- The RBD region was amplified using Q5® High-Fidelity DNA Polymerase using the
   forward primer 5' -
- 182 TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGccagatgattttacaggctgcg-3' and

- 183 reverse primer 5'-
- 184 GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGgaaagtactactactctgtatggttgg-3',
- 185 which incorporate Illumina adaptors. PCR performed as follows: 98°C for 30 seconds,
- followed by 40 cycles of 98°C 5 seconds, 53°C for 15 seconds and 65°C for 1 minute and
- 187 a final extension at 65°C for 1 minute.

**Targeted Sequencing.** The RBD amplicons were purified using AMPure XP beads

- 189 (Beckman Coulter). Index PCR was performed using the Nextera DNA CD Indexes kit
- 190 (Illumina) with 2X KAPA HiFi HotStart ReadyMix (Roche), and indexed PCR products
- <sup>191</sup> purified using AMPure beads. The indexed libraries were quantified using the Qubit 3.0
- and Qubit dsDNA HS Assay Kit and diluted in 10 mM Tris-HCl to a final concentration of
- approximately 0.3 ng/ $\mu$ L (1 nM). The libraries were pooled together and diluted to a final
- concentration of 50 pM. Before sequencing on an Illumina iSeq100, a 10% spike-in of
- 195 50 pM PhiX control v3 (Illumina) was added to the pooled library.
- 196 **Bioinformatics.** Sequencing data was uploaded to the BaseSpace Sequence Hub, and
- the reads demultiplexed using a FASTQ generation script. Reads were processed using
- the published Geneious workflows for preprocessing of NGS reads and assembly of
- 199 SARS-CoV-2 amplicons (https://help.geneious.com/hc/en-us/articles/360045070991-
- 200 Assembly-of-SARS-CoV-2-genomes-from-tiled-amplicon-Illumina-sequencing-using-
- 201 Geneious-Prime and https://help.geneious.com/hc/en-us/articles/360044626852-Best-
- 202 practice-for-preprocessing-NGS-reads-in-Geneious-Prime). Paired reads were trimmed,
- and the adapter sequences removed with the BBDuk plugin. Trimmed reads were
- merged and aligned to the SARS-CoV-2 reference genome MN908947. Variants were
- called using the Annotate and Predict Find Variations/SNPs in Geneious and verified by
- using the V-PIPE SARS-CoV-2 application (<u>https://cbg-ethz.github.io/V-pipe/sars-cov-</u>
- 207 <u>2/</u>)(28).

# 208 Data Availability

- 209 Raw sequencing reads are available in NCBI's Sequence Read Archive (SRA) under
- 210 accession # PRJNA715712.

# 211 ACKNOWLEDGEMENTS

- The research described herein would not be possible if not for the assistance and
- support of a wide-range of organizations and individuals that came together to address
- the shared calamity that is the COVID-19 pandemic. We thank Gina Behnke, Esmeraldo
- 215 Castro, Francoise Chauvin, Alexander Clare, Pilar Domingo-Calap, Pam Elardo, Raul
- Gonzalez, Crystal Hepp, Catherine Hoar, Dimitrios Katehis, William Kelly, Samantha
- 217 McBride, Hope McGibbon, Hilary Millar, Samantha Patinella, Krish Ramalingam, Andrea
- 218 Silverman, Jasmin Torres, Arvind Varsani, Peter Williamsen for support, advice,
- discussions, and feedback. This work was funded in part by the New York City
- 220 Department of Environmental Protection. The Water Research Foundation, the NSF
- 221 Research Coordination Network for Wastewater Surveillance for SARS-CoV-2 and


- 222 Qiagen Inc. provided resources, materials and supplies, technical support, and
- community support.

#### 224 FIGURE LEGEND

- Figure 1. Frequencies of reads associated with five selected mutations associated with
- 226 SARS-CoV-2 Variants of Concern from wastewater obtained from 14 NYC wastewater
- treatment plants on two separate dates.

228

### 229 Figure 1





231

232

#### 233 **REFERENCES**

234 Alpert T, Lasek-Nesselquist E, Brito AF, Valesano AL, Rothman J, MacKay MJ, Petrone ME, 1. 235 Breban MI, Watkins AE, Vogels CBF, Russell A, Kelly JP, Shudt M, Plitnick J, Schneider E, 236 Fitzsimmons WJ, Khullar G, Metti J, Dudley JT, Nash M, Wang J, Liu C, Hui P, Muyombwe A, 237 Downing R, Razeg J, Bart SM, Murphy S, Neal C, Laszlo E, Landry ML, Cook PW, Fauver JR, Mason 238 CE, Lauring AS, St George K, MacCannell DR, Grubaugh ND. 2021. Early introductions and 239 community transmission of SARS-CoV-2 variant B.1.1.7 in the United States. medRxiv : the 240 preprint server for health sciences doi:10.1101/2021.02.10.21251540:2021.02.10.21251540. 241 2. Washington NL, Gangavarapu K, Zeller M, Bolze A, Cirulli ET, Schiabor Barrett KM, Larsen BB, 242 Anderson C, White S, Cassens T, Jacobs S, Levan G, Nguyen J, Ramirez JM, Rivera-Garcia C, 243 Sandoval E, Wang X, Wong D, Spencer E, Robles-Sikisaka R, Kurzban E, Hughes LD, Deng X, Wang 244 C, Servellita V, Valentine H, De Hoff P, Seaver P, Sathe S, Gietzen K, Sickler B, Antico J, Hoon K, 245 Liu J, Harding A, Bakhtar O, Basler T, Austin B, Isaksson M, Febbo P, Becker D, Laurent M, 246 McDonald E, Yeo GW, Knight R, Laurent LC, de Feo E, Worobey M, Chiu C, Suchard MA, et al. 247 2021. Genomic epidemiology identifies emergence and rapid transmission of SARS-CoV-2 B.1.1.7 248 in the United States. medRxiv : the preprint server for health sciences 249 doi:10.1101/2021.02.06.21251159:2021.02.06.21251159. 250 Leung K, Shum MH, Leung GM, Lam TT, Wu JT. 2021. Early transmissibility assessment of the 3. 251 N501Y mutant strains of SARS-CoV-2 in the United Kingdom, October to November 2020. Euro 252 surveillance : bulletin Europeen sur les maladies transmissibles = European communicable 253 disease bulletin 26:2002106. 254 Zhao S, Lou J, Cao L, Zheng H, Chong MKC, Chen Z, Chan RWY, Zee BCY, Chan PKS, Wang MH. 4. 255 2021. Quantifying the transmission advantage associated with N501Y substitution of SARS-CoV-256 2 in the UK: an early data-driven analysis. J Travel Med 28. 257 5. Hunter PR, Brainard J, Grant A. 2021. The Impact of the November 2020 English National 258 Lockdown on COVID-19 case counts. medRxiv 259 doi:10.1101/2021.01.03.21249169:2021.01.03.21249169. 260 6. Volz E, Mishra S, Chand M, Barrett JC, Johnson R, Geidelberg L, Hinsley WR, Laydon DJ, Dabrera 261 G, O'Toole Á, Amato R, Ragonnet-Cronin M, Harrison I, Jackson B, Ariani CV, Boyd O, Loman NJ, 262 McCrone JT, Gonçalves S, Jorgensen D, Myers R, Hill V, Jackson DK, Gaythorpe K, Groves N, 263 Sillitoe J, Kwiatkowski DP, Flaxman S, Ratmann O, Bhatt S, Hopkins S, Gandy A, Rambaut A, Ferguson NM. 2021. Transmission of SARS-CoV-2 Lineage B.1.1.7 in England: Insights from 264 265 linking epidemiological and genetic data. medRxiv 266 doi:10.1101/2020.12.30.20249034:2020.12.30.20249034. Collier DA, De Marco A, Ferreira I, Meng B, Datir R, Walls AC, Kemp SS, Bassi J, Pinto D, Fregni CS, 267 7. 268 Bianchi S, Tortorici MA, Bowen J, Culap K, Jaconi S, Cameroni E, Snell G, Pizzuto MS, Pellanda AF, 269 Garzoni C, Riva A, Elmer A, Kingston N, Graves B, McCoy LE, Smith KG, Bradley JR, Temperton N, 270 Ceron-Gutierrez LL, Barcenas-Morales G, Harvey W, Virgin HW, Lanzavecchia A, Piccoli L, 271 Doffinger R, Wills M, Veesler D, Corti D, Gupta RK. 2021. SARS-CoV-2 B.1.1.7 sensitivity to mRNA 272 vaccine-elicited, convalescent and monoclonal antibodies. medRxiv 273 doi:10.1101/2021.01.19.21249840. 274 8. Tada T, Dcosta BM, Samanovic-Golden M, Herati RS, Cornelius A, Mulligan MJ, Landau NR. 2021. 275 Neutralization of viruses with European, South African, and United States SARS-CoV-2 variant spike proteins by convalescent sera and BNT162b2 mRNA vaccine-elicited antibodies. bioRxiv 276 277 doi:10.1101/2021.02.05.430003. 278 9. Graham C, Seow J, Huettner I, Khan H, Kouphou N, Acors S, Winstone H, Pickering S, Pedro 279 Galao R, Jose Lista M, Jimenez-Guardeno JM, Laing AG, Wu Y, Joseph M, Muir L, Ng WM,

280		Duyvesteyn HME, Zhao Y, Bowden TA, Shankar-Hari M, Rosa A, Cherepanov P, McCoy LE,
281		Hayday AC, Neil SJD, Malim MH, Doores KJ. 2021. Impact of the B.1.1.7 variant on neutralizing
282		monoclonal antibodies recognizing diverse epitopes on SARS-CoV-2 Spike. bioRxiv
283		doi:10.1101/2021.02.03.429355.
284	10.	Dennehy JJ. 2017. Evolutionary ecology of virus emergence. Annals of the New York Academy of
285	10.	Sciences 1389:124-146.
285	11.	Furuse Y. 2021. Genomic sequencing effort for SARS-CoV-2 by country during the pandemic. Int J
	11.	Infect Dis 103:305-307.
287	10	
288	12.	Johansson MA, Quandelacy TM, Kada S, Prasad PV, Steele M, Brooks JT, Slayton RB, Biggerstaff
289		M, Butler JC. 2021. SARS-CoV-2 Transmission From People Without COVID-19 Symptoms. JAMA
290		Network Open 4:e2035057-e2035057.
291	13.	Chen Y, Chen L, Deng Q, Zhang G, Wu K, Ni L, Yang Y, Liu B, Wang W, Wei C, Yang J, Ye G, Cheng
292		Z. 2020. The presence of SARS-CoV-2 RNA in the feces of COVID-19 patients. J Med Virol 92:833-
293		840.
294	14.	Walsh KA, Jordan K, Clyne B, Rohde D, Drummond L, Byrne P, Ahern S, Carty PG, O'Brien KK,
295		O'Murchu E, O'Neill M, Smith SM, Ryan M, Harrington P. 2020. SARS-CoV-2 detection, viral load
296		and infectivity over the course of an infection. J Infect 81:357-371.
297	15.	Larsen DA, Wigginton KR. 2020. Tracking COVID-19 with wastewater. Nature Biotechnology
298		38:1151-1153.
299	16.	Medema G, Been F, Heijnen L, Petterson S. 2020. Implementation of environmental surveillance
300	10.	for SARS-CoV-2 virus to support public health decisions: Opportunities and challenges. Current
301		Opinion in Environmental Science & Health 17:49-71.
301	17.	Ahmed W, Tscharke B, Bertsch PM, Bibby K, Bivins A, Choi P, Clarke L, Dwyer J, Edson J, Nguyen
	17.	
303		TMH, O'Brien JW, Simpson SL, Sherman P, Thomas KV, Verhagen R, Zaugg J, Mueller JF. 2021.
304		SARS-CoV-2 RNA monitoring in wastewater as a potential early warning system for COVID-19
305		transmission in the community: A temporal case study. Science of The Total Environment
306		761:144216.
307	18.	Crits-Christoph A, Kantor RS, Olm MR, Whitney ON, Al-Shayeb B, Lou YC, Flamholz A, Kennedy
308		LC, Greenwald H, Hinkle A, Hetzel J, Spitzer S, Koble J, Tan A, Hyde F, Schroth G, Kuersten S,
309		Banfield JF, Nelson KL. 2021. Genome Sequencing of Sewage Detects Regionally Prevalent SARS-
310		CoV-2 Variants. mBio 12:e02703-20.
311	19.	Fontenele RS, Kraberger S, Hadfield J, Driver EM, Bowes D, Holland LA, Faleye TOC, Adhikari S,
312		Kumar R, Inchausti R, Holmes WK, Deitrick S, Brown P, Duty D, Smith T, Bhatnagar A, Yeager RA,
313		Holm RH, Hoogesteijn von Reitzenstein N, Wheeler E, Dixon K, Constantine T, Wilson MA, Lim
314		ES, Jiang X, Halden RU, Scotch M, Varsani A. 2021. High-throughput sequencing of SARS-CoV-2 in
315		wastewater provides insights into circulating variants. medRxiv
316		doi:10.1101/2021.01.22.21250320.
317	20.	Martin J, Klapsa D, Wilton T, Zambon M, Bentley E, Bujaki E, Fritzsche M, Mate R, Majumdar M.
318	20.	2020. Tracking SARS-CoV-2 in Sewage: Evidence of Changes in Virus Variant Predominance
319	21	during COVID-19 Pandemic. Viruses 12.
320	21.	Trujillo M, Cheung K, Gao A, Hoxie I, Kannoly S, Kubota N, San KM, Smyth DS, Dennehy JJ. 2021.
321		Protocol for Safe, Affordable, and Reproducible Isolation and Quantitation of SARS-CoV-2 RNA
322		from Wastewater. medRxiv doi:10.1101/2021.02.16.21251787:2021.02.16.21251787.
323	22.	Pecson BM, Darby E, Haas CN, Amha YM, Bartolo M, Danielson R, Dearborn Y, Di Giovanni G,
324		Ferguson C, Fevig S, Gaddis E, Gray D, Lukasik G, Mull B, Olivas L, Olivieri A, Qu Y, Consortium SA-
325		C-I. 2021. Reproducibility and sensitivity of 36 methods to quantify the SARS-CoV-2 genetic
326		signal in raw wastewater: findings from an interlaboratory methods evaluation in the U.S.
327		Environmental Science: Water Research & Technology doi:10.1039/D0EW00946F.

- Lasek-Nesselquist E, Lapierre P, Schneider E, St. George K, Pata J. 2021. The localized rise of a
   B.1.526 variant containing an E484K mutation in New York State. medRxiv
- doi:10.1101/2021.02.26.21251868:2021.02.26.21251868.
- Annavajhala MK, Mohri H, Zucker JE, Sheng Z, Wang P, Gomez-Simmonds A, Ho DD, Uhlemann
  A-C. 2021. A Novel SARS-CoV-2 Variant of Concern, B.1.526, Identified in New York. medRxiv
  doi:10.1101/2021.02.23.21252259:2021.02.23.21252259.
- 334 25. CDC.gov. 2021. <u>https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/variant-</u>
   335 <u>surveillance/variant-info.html</u>. Accessed March 19.
- Deng X, Garcia-Knight MA, Khalid MM, Servellita V, Wang C, Morris MK, Sotomayor-González A,
  Glasner DR, Reyes KR, Gliwa AS, Reddy NP, Sanchez San Martin C, Federman S, Cheng J, Balcerek
  J, Taylor J, Streithorst JA, Miller S, Kumar GR, Sreekumar B, Chen P-Y, Schulze-Gahmen U, Taha
  TY, Hayashi J, Simoneau CR, McMahon S, Lidsky PV, Xiao Y, Hemarajata P, Green NM, Espinosa
- 340A, Kath C, Haw M, Bell J, Hacker JK, Hanson C, Wadford DA, Anaya C, Ferguson D, Lareau LF,341Frankino PA, Shivram H, Wyman SK, Ott M, Andino R, Chiu CY. 2021. Transmission, infectivity,
- and antibody neutralization of an emerging SARS-CoV-2 variant in California carrying a L452R
- 343 spike protein mutation. medRxiv doi:10.1101/2021.03.07.21252647:2021.03.07.21252647.
- Lasek-Nesselquist E, Pata J, Schneider E, George KS. 2021. A tale of three SARS-CoV-2 variants
  with independently acquired P681H mutations in New York State. medRxiv
  doi:10.1101/2021.03.10.21253285:2021.03.10.21253285.
- Posada-Céspedes S, Seifert D, Topolsky I, Jablonski KP, Metzner KJ, Beerenwinkel N. 2021. Vpipe: a computational pipeline for assessing viral genetic diversity from high-throughput data.
  Bioinformatics doi:10.1093/bioinformatics/btab015.
- 350

351